References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046–1060.
- Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333–6338.
- Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–2221.
- Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 2014;4:e191.
- Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014; 28:1725–1735.
- Glitza IC, Lu G, Shah R, et al. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 2015;56:602–607.
- Moreau P, Planche L, Attal M, et al. The combination of ISS 3, high LDH and t(4;14) and/or del(17p) identify a simple prognostic index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation, and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. Blood 2012;120(Suppl. 1) Abstract 598.
- Holien T, Vatsveen TK, Hella H, et al. Addiction to c-MYC in multiple myeloma. Blood 2012;120:2450–2453.
- Kuehl WM, Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood 2012;120:2351–2352.
- Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904–917.
- Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014;123:697–705.